NBS News Alert Neostem (NBS) 3.27 12/25/2014 11:58:01

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Neostem (NBS) 3.27 $NBS

Cell Therapy 2015: With Maturity Comes Promise
Life Sciences Report - Seeking Alpha - Wed Dec 24, 6:41AM CST
A number of new and innovative medical paradigms are being explored by companies in the life sciences sector, with one of the front-runners being cell therapy - a disruptive technology that has, in the past few years, progressed out of preclinical...
KOOL: 1.13 (+0.04), AGEN: 3.85 (unch), INO: 9.11 (-0.09), NBS: 3.27 (+0.02), OSIR: 14.87 (+0.13), TEVA: 57.09 (+0.33), ATHX: 1.30 (-0.03)

PCT, a NeoStem Company, Presented Lovo(R) Cell Processing System Data at IBC Life Sciences' Commercialization of Cell, Gene & Immunotherapies Conference
GlobeNewswire - Mon Dec 15, 6:39AM CST
NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell based therapeutics, and Progenitor Cell Therapy, LLC ("PCT" , a NeoStem company and a leading contract development and manufacturing organization in the cellular therapy industry, announced that Dr. Ian Gaudet, Senior Engineer with PCT's Engineering and Innovation Center, presented results of PCT's most recent study to generate data on the performance of the Lovo Cell Processing System.
NBS: 3.27 (+0.02)

NeoStem's Subsidiary, Progenitor Cell Therapy, Earns AABB Re-Accreditation for Its Allendale, NJ Manufacturing Facility
GlobeNewswire - Mon Dec 08, 6:30AM CST
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company" , a biopharmaceutical company developing novel cell based therapeutics, and its subsidiary, Progenitor Cell Therapy, LLC ("PCT" , announced today that PCT has been awarded re-accreditation by AABB (formerly known as the American Association of Blood Banks) in the category of "Cell Therapy Activity: Cord Blood - Processing, Storage and Distribution" for its Allendale, NJ facility. Accreditation follows an intensive on-site assessment by specially trained AABB assessors and establishes that the level of technical and administrative performance within the facility meets or exceeds the standards set by AABB.
NBS: 3.27 (+0.02)

Insider Trading Alert - UGI, NBS And MACK Traded By Insiders
at The Street - Fri Dec 05, 10:15AM CST
Stocks with insider trader activity include UGI, NBS and MACK
MACK: 10.91 (+0.36), UGI: 38.27 (+0.64), NBS: 3.27 (+0.02)

NeoStem, Inc. - "Initial Trial Results of PreSERVE AMI: The Meaningful Clinical Relevance of the Data"
ACCESSWIRE - Tue Dec 02, 7:33AM CST
New York, NY / ACCESSWIRE / December 2, 2014 / NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO, Dr. Robin L. Smith. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
NBS: 3.27 (+0.02)

NeoStem and PCT, A NeoStem Company, to Present at Multiple December Conferences
GlobeNewswire - Mon Dec 01, 6:30AM CST
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company" , a biopharmaceutical company developing novel cell based therapies, announced today that the Company and its subsidiary, Progenitor Cell Therapy, LLC ("PCT" , will present at multiple upcoming conferences in December.
NBS: 3.27 (+0.02)

NeoStem to Host Key Opinion Leader Event Webcast on December 1, 2014
GlobeNewswire - Wed Nov 26, 6:30AM CST
NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell based therapeutics, announced today that it will host a Key Opinion Leader event webcast on Monday, December 1, 2014 from 4:30 to 5:30 PM EST.
NBS: 3.27 (+0.02)

NeoStem CSO Dr. Robert Preti Elected Vice Chairman of the Alliance for Regenerative Medicine
GlobeNewswire - Tue Nov 25, 6:30AM CST
NeoStem, Inc. (Nasdaq:NBS) announced today that Dr. Robert Preti, the Company's Chief Scientific Officer and President of its subsidiary, Progenitor Cell Therapy ("PCT" , has been elected Vice Chairman of the Alliance for Regenerative Medicine (ARM), an international organization representing the regenerative medicine and advanced therapies community. Dr. Preti will serve in this role effective January 1, 2015.
NBS: 3.27 (+0.02)

NeoStem Provides Further Information Regarding the Design of the Phase 2 PreSERVE AMI Clinical Trial
GlobeNewswire - Fri Nov 21, 2:09PM CST
NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell based therapeutics, announced on November 17 initial positive data from its 161 patient Phase 2 PreSERVE AMI (or acute myocardial infarction) clinical trial.
NBS: 3.27 (+0.02)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 11:46AM CST

LEJU: 10.72 (+0.28), GEOS: 26.42 (-0.61), LXRX: 0.90 (+0.02), OTIV: 1.71 (unch), GME: 33.39 (-1.24), ARUN: 18.45 (+0.40), NBS: 3.27 (+0.02), PHMD: 1.46 (-0.03), AMDA: 0.64 (-0.01), CANF: 3.70 (+0.01), MOLG: 2.92 (+0.03), WAIR: 14.20 (unch), EDAP: 1.97 (+0.01), FWM: 2.80 (-0.03), GERN: 3.06 (+0.05), OCRX: 5.77 (+0.02), NGVC: 26.39 (+0.09), SFUN: 7.17 (-0.03), EJ: 7.48 (+0.17), BGI: 1.66 (+0.20)

Hot Stock: Neostem, Shares Drop 8.8% (NBS)
Comtex SmarTrend(R) - Fri Nov 21, 10:36AM CST
Neostem (AMEX:NBS) is one of today's worst performing low-priced stocks, down 8.8% to $4.06 on 1.7x average daily volume. Thus far today, Neostem has traded 701,000 shares, vs. average volume of 415,000 shares per day. The stock has underperformed the Dow (-8.8% to the Dow's 0.7%) and underperformed the S&P 500 (-8.8% to the S&P's 0.7%) during today's trading.
NBS: 3.27 (+0.02)

NeoStem: Changing The Goalposts Midgame And A Potentially Biased Analyst
Bleecker Street Research - Seeking Alpha - Fri Nov 21, 8:30AM CST
On November 14, Maxim Group analyst Jason Kolbert put out a bullish note on NeoStem, Inc. (NASDAQ: NBS ) in front of Phase 2 data. The note combined with apparent market enthusiasm for this data helped propel shares up 40% in two weeks before the...
NBS: 3.27 (+0.02)

NeoStem's NBS10 And Data That Matters To Regulators
Steven Giardino - Seeking Alpha - Fri Nov 21, 6:30AM CST
On Monday evening, NeoStem (NASDAQ: NBS ) reported interim data on their double-blind placebo-controlled 161-patient Ph II study testing NBS10 in patients that had experienced acute myocardial infarction (AMI). With the exception of a noticeable...
BAX: 74.45 (-0.04), NBS: 3.27 (+0.02)

Wound Care Market by Type (Traditional (Wound Closure, Anti infective), Basic (Films, Cleansing), Advanced (Hydrogels, Hydrocolloids, Alginate, Collagen), Active (Artificial Skin & Skin Substitutes), Pressure Relief Devices, NPWT) - Global Forecast to 201
PR Newswire - Wed Nov 19, 7:58PM CST
The global wound care market is expected to reach $18.3 billion by 2019 from $15.6 billion in 2014, growing at a CAGR of 3.2% from 2014 to 2019. The global wound care market is categorized on the basis of product and geography. The active wound care market is expected to register the highest growth rate in the wound care market during the forecast period, owing to the continuous launch of new and advanced products.
NBS: 3.27 (+0.02)

Neostem (NBS): Today's Weak On High Volume Stock
at The Street - Wed Nov 19, 9:02AM CST
Trade-Ideas LLC identified Neostem (NBS) as a weak on high relative volume candidate
NBS: 3.27 (+0.02)

NeoStem, Inc. - "Encouraging Findings from PreSERVE AMI"
ACCESSWIRE - Wed Nov 19, 7:44AM CST
New York, NY / ACCESSWIRE / November 19, 2014 / NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Chief Visionary Officer and Chief Medical Officer of Progenitor Cell Therapy, Dr. Andrew L. Pecora. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
NBS: 3.27 (+0.02)

NeoStem, Inc. - "PreSERVE AMI Phase 2 Results"
ACCESSWIRE - Tue Nov 18, 12:38PM CST
New York, NY / ACCESSWIRE / November 18, 2014 / NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Chief Medical Officer, Dr. Douglas W. Losordo. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
NBS: 3.27 (+0.02)

NeoStem (NBS) Stock Plummets Today on Disappointing Cardiac Stem-Cell Therapy Data
at The Street - Tue Nov 18, 11:40AM CST
Shares of NeoStem (NBS) plunged in late morning trading Monday after the biotech company announced poor results from a trial of its proprietary cardiac stem-cell therapy NBS10.
NBS: 3.27 (+0.02)

NeoStem's Stem Cell Therapy Fails Mid-Stage Heart Attack Study
at The Street - Tue Nov 18, 9:16AM CST
Using stem cells to repair damaged hearts is a great story, but proof remains elusive.
NBS: 3.27 (+0.02)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
E-Rate Risk and Data Center Rules Demand Attention

Updated Category News Views 71

America’s digital plumbing is getting squeezed at both ends: the public connections nobody notices until they fail, and the industrial-scale computing boom everybody suddenly wants built yesterday. Connected Nation’s two bonus podcast episodes from the Broadband Nation Expo in New Orleans put those pressures side by side, and it is a more useful pairing than it may...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 51

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 95

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
ADFW 2026 Builds a Bigger Stage for Global Capital

Updated Category News Views 46

Abu Dhabi is not merely booking conference rooms this December; it is assembling a very deliberate display of financial muscle. Abu Dhabi Finance Week runs from 7 to 10 December 2026, and ADGM says its fifth edition will carry its largest-ever programme of partner-led activity. That is a promotional claim, sure, but the partner list is substantial enough that investors...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 97

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 99

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
Cedars-Sinai and nference Build a Living Data Engine

Updated Category News Views 175

Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...

Continue Reading
Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 60

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 57

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading

Top 5 Most Recently Viewed Articles

Natural Food Color Industry Expected to Thrive by 2035

Updated Category News Views 167

Revitalizing the Natural Food Colors Market The natural food colors market is poised for remarkable growth, projected to expand from USD 2.01 billion to USD 4.03 billion by 2035. Market analysts suggest this surge will take place at a Compound Annual Growth Rate (CAGR) of 7.8%. This transformation is largely attributed to a shift in consumer preferences, regulatory...

Continue Reading
Fang Holdings Strengthens Leadership with Board Changes

Updated Category News Views 98

Fang Holdings Limited Announces Leadership Changes Fang Holdings Limited (OTC: SFUNY) has officially confirmed changes within its board of directors, marking an important phase for the company. As a prominent real estate Internet portal, Fang is committed to providing exceptional services to its users, and these changes in leadership are expected to support its strategic...

Continue Reading
NovaBridge's Visara Appoints Leaders to Propel Eye Treatment

Updated Category News Views 235

NovaBridge's Strategic Moves in Ophthalmology In a significant step forward for innovative treatment in ophthalmology, NovaBridge Biosciences (NASDAQ: NBP) has announced new appointments at its subsidiary, Visara, Inc. Cadmus C. Rich, MD, MBA, has been named Chief Medical Officer, while Carlos Quezada-Ruiz, MD, FASRS, takes the role of Chair of the Scientific Advisory...

Continue Reading
Celebrating Excellence: The Grossman Group's 25-Year Journey

Updated Category News Views 274

The Grossman Group Celebrates 25 Years of Communication Excellence In a prestigious recognition, The Grossman Group has earned the title of Best Small Agency at the Public Relations Society of America's 2025 Silver Anvil Awards. This honor comes during a significant milestone—the company's 25th anniversary—marked by years of dedication to enhancing internal...

Continue Reading
GiGi's Playhouse Celebrates the Opening of Its 61st Center in the Northwest

Updated Category News Views 360

GiGi's Playhouse unveiled its 61st Achievement Center back in the fall of a recent year, pushing forward its mission to uplift individuals impacted by Down syndrome. The grand opening of this center wasn’t just another launch—it was a culmination of seven years filled with passion, community spirit, and unwavering dedication from parents who aimed to create a haven...

Continue Reading